5.9.02: Second Annual Biotechnology Industry Conference Issue
Five analysts, three experts, two money managers and top management from fourteen sector firms examine the biotechnology sector in this special 98-page Second Annual Biotechnology Industry Conference issue from The Wall Street Transcript.

    Online subscribers to the Healthcare sector also get
    Canadian Biotechnology Issue & Healthcare Information Technology Issue

  1. Biotechnology & Better Communication - In an in-depth (2,600 words) Expert Interview, Donald R. Johnston, Vice President/Group Publisher at American Heath Consultants, examines the outlook for the sector.
  2. Innovative Biopharmaceutical Companies - In an in-depth (3,200 words) Analyst Interview, Ed Gordon, Managing Director and co-Head of Punk Ziegel & Company, examines the outlook for the sector and shares specific stock recommendations.
  3. The BIO & The Need for Advocacy - In an in-depth (3,300 words) Expert Interview, Carl B. Feldbaum, President of the Biotechnology Industry Organization academic institutions, examines the outlook for the sector.
  4. Reporting on Biotechnology - In an in-depth (2,900 words) Expert Interview, Justin Gillis, Reporter for The Washington Post covering the biotechnology industry, examines the outlook for the sector.
  5. Therapeutic-Focused Biotechnology - In an in-depth (3,100 words) Analyst Interview, Srinivas Akkaraju, Analyst at J.P. Morgan Partners LLC, examines the outlook for the sector and shares specific stock recommendations.
  6. Investing in Biotechnology - In an in-depth (2,900 words) Analyst Interview, Franklin M. Berger, Vice President in the Equity Research Department at JP Morgan H&Q, examines the outlook for the sector and shares specific stock recommendations.
  7. Investing in Biotechnology - Money Manager Interview, Mary Ann Gray, Analyst focusing on both public and private healthcare investments at Federated Kaufmann Fund, examines portfolio management strategies in this timely and deeply informative 2,600-word interview from The Wall Street Transcript.
  8. Biotechnology Investment Issues - In an in-depth (2,700 words) Analyst Interview, Dennis J. Purcell, Senior Managing Director at Perseus - Soros BioPharmaceutical Fund, LP, examines the outlook for the sector and shares specific stock recommendations.
  9. Biotechnology Stocks - In an in-depth (2,900 words) Analyst Interview, Eric Schmidt, Managing Director and Senior Research Analyst covering biotechnology stocks for SG Cowen Securities Corporation, examines the outlook for the sector and shares specific stock recommendations.
  10. Biotechnology & Venture Capital - Money Manager Interview, Carl L. Gordon, founding General Partner of OrbiMed Advisors LLC., examines portfolio management strategies in this timely and deeply informative 3,900-word interview from The Wall Street Transcript.
  11. CEO and Sponsored interviews (average 2,500 words). Top management of fourteen sector firms examine the outlook for their firm and the sector. Firms include:
    Deloitte & Touche, PPL Therapeutics Plc, Infigen, Incara Pharmaceuticals, Immerge BioTherapeutics, Vertex Pharmaceuticals, OSI Pharmaceuticals, PR21, Aastrom Biosciences, Allos Therapeutics, Dendreon, SuperGen, AVANT Immunotherapeutics, McDonnell Boehnen Hulbert & Berghoff
    12. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE